Clinical trial · Interventional
Cognitive Rehabilitation of Glioma Patients
Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study
NCT00256425CI-TRIAL-00001359unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether cognitive rehabilitation is effective in patients with gliomas (brain tumour), by comparing direct and follow-up neuropsychological functioning and quality of life of the experimental group to the control group.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cognition Disorders | — | UNRESOLVED | — |
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cognitive rehabilitation | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- neuropsychological measures of attention (test scores)
- timeFrame
- baseline, immediately after 6 weeks and at 6-month follow-up
Secondary outcomes (3)
- measure
- neuropsychological measures of memory and executive functioning (test scores)
- timeFrame
- baseline, immediately after 6 weeks and at 6-month follow-up
- measure
- subjective neuropsychological functioning (questionnaires)
- timeFrame
- baseline, immediately after 6 weeks and at 6-month follow-up
- measure
- quality of life (questionnaires)
- timeFrame
- baseline, immediately after 6 weeks and at 6-month follow-up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * adult patients with a histologically proven low-grade glioma or presumed (i.e., suspected) low-grade glioma based on both clinical and MR imaging feature, and * adult patients with an anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligo-astrocytoma) under age 50 and with good performance status (KPS \> 70); * who are clinically stable for a minimum of 6 months prior to study entry (as determined by recent CT or MRI imaging) and no anti-tumor treatment during that period of time (i.e., surgery, radiotherapy, chemotherapy, corticosteroids); * who report at least one symptom of impaired cognitive functioning based on a standardized self-report questionnaire, administered by researcher; * and who meet criteria for neuropsychological impairment based on objective test results (assessed by researcher). Exclusion Criteria: * lack of basic proficiency in Dutch; * IQ below 85; * severe reading problems; * an additional (history of) neurological or psychiatric disorder; * participating in a concurrent study in which neuropsychological testing and/or health-related quality of life assessments are involved
References
Publications (2)
- BACKGROUNDKlein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJ. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002 Nov 2;360(9343):1361-8. doi: 10.1016/s0140-6736(02)11398-5. PMID 12423981
- BACKGROUNDTaphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004 Mar;3(3):159-68. doi: 10.1016/S1474-4422(04)00680-5. PMID 14980531